Interleukin-12 gene therapy in combination with bevacizumab and pegylated liposomal doxorubicin for treatment of disseminated ovarian cancer

被引：0
|
作者：
Fewell, Jason G.
Matar, Majed M.
Rice, Jennifer
McClure, Diane
Brunhoeber, Elaine
Sparks, Jeff
Greenleaf, Stefanie
Smith, Kelley
Anwer, Khursheed
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2078
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)
    O'Cearbhaill, Roisin
    Sill, Michael
    Duong, Hoa
    Waggoner, Steven
    Grisham, Rachel
    Backes, Floor
    Mannel, Robert
    Tanyi, Janos
    Powell, Matthew
    Mathews, Cara
    Ghamande, Sharad
    Mcnally, Leah
    Olawaiye, Alexander
    Bender, David
    Duska, Linda
    Lankes, Heather
    Zamarin, Dmitriy
    Schilder, Russell
    Bookman, Michael
    Aghajanian, Carol
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A4 - A4
  • [42] Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience
    Dear, Rachel F.
    Gao, Bo
    Harnett, Paul
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2010, 6 (01) : 66 - 73
  • [43] The role of bevacizumab in combination with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent or refractory ovarian cancers.
    Kouta, H.
    Kudoh, K.
    Takano, M.
    Kikuchi, R.
    Kita, T.
    Goto, T.
    Furuya, K.
    Kikuchi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer Foreword
    Clare, John
    FUTURE ONCOLOGY, 2013, 9 (12) : 1 - 1
  • [45] Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer
    Pignata, Sandro
    Lauraine, Eric Pujade
    du Bois, Andreas
    Pisano, Carmela
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 73 (01) : 23 - 30
  • [46] Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma
    Manochakian, Rarni
    Miller, Kena C.
    Chanan-Khan, Asher Alban
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (04): : 266 - 271
  • [47] Combination of bevacizumab (A) and pegylated-liposomal doxorubicin (PLD) (PLD-A) in sarcoma (SAR).
    Haddad, P. A.
    Skubitz, K. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 533S - 533S
  • [48] Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series
    Ku, Geoffrey Y.
    Lopes, Gilberto De Lima, Jr.
    Chang, Alex Y.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 174 - 179
  • [49] Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
    Jones, Robin Lewis
    Herzog, Thomas J.
    Patel, Shreyaskumar
    von Mehren, Margaret
    Schuetze, Scott
    Van Tine, Brian Andrew
    Coleman, Robert L.
    Triantos, Spyridon
    Hu, Peter
    Shalaby, Waleed
    McGowan, Tracy
    Monk, Bradley J.
    Demetri, George D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer
    Verhaar-Langereis, M
    Karakus, A
    Van Eijkeren, M
    Voest, E
    Witteveen, E
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) : 65 - 70
12345